Skip to content

Depreciation at other companies

Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Glaukos logo
GlaukosGKOS
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's depreciation?
Kodiak Sciences Inc (KOD) reported depreciation of $4.11M in Q1 2026.
How has Kodiak Sciences Inc's depreciation changed year-over-year?
Kodiak Sciences Inc's depreciation decreased by 10.7% year-over-year, from $4.6M to $4.11M.
What is the long-term trend for Kodiak Sciences Inc's depreciation?
Over 4 years (2021 to 2025), Kodiak Sciences Inc's depreciation has grown at a 106.8% compound annual growth rate (CAGR), from $1M to $18.33M.